Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
154
resultados
Última actualización
16/09/2025 [06:55:00]
Resumen de: WO2025188313A1
A method and system for establishing and executing a dynamic titration protocol for administration of an antidiabetic is disclosed. The method may include establishing an initial titration protocol and then applying an aggressiveness level to the initial titration protocol to obtain an initial use titration protocol. The initial use titration protocol may then be executed with a patient and glucose monitoring data may be received from the patient. The monitoring data may be used to perform a failsafe monitoring procedure and a revised aggressiveness level and titration protocol may be determined based on the results of the failsafe monitoring.
Resumen de: WO2025188465A1
Described herein are systems and methods for non-invasive glucose detection using an optical sensing apparatus. The optical sensing apparatus comprises one or more single-photon avalanche diodes (SPADs) and one or more processors. The one or more SPADs may be configured to receive light pulses having one or more wavelengths that have interacted with biological tissues over a plurality of time cycles and convert the light pulses into a plurality of electrical signals. Each of the one or more SPADs may comprise an absorption region formed on a substrate, wherein the absorption region comprises germanium or germanium containing tin, and wherein the substrate comprises silicon. The one or more processors may be configured to identify, for each of the plurality of time cycles, particular time slots representing a time duration that each of the light pulses has interacted with glucose molecules and determine one or more characteristics of glucose molecules.
Resumen de: WO2025188641A1
A system includes an analyte measurement system and a software application operatively coupled to the analyte measurement system. The analyte measurement system is configured to measure an analyte of a patient. The software application is configured to retrieve sensor data of the analyte level, analyte rate of change, or both; detect at least one condition associated with the sensor data; and provide a notification to the patient associated with the at least one detected condition. Advantageously the system can detect current or impending adverse conditions (such as an insulin deficiency), provide custom notifications (e.g., warnings, recommendations, guidance) to the patient to act, prompt the patient for additional information relevant to the detected condition, continuously monitor glucose and ketone levels in real-time, control insulin delivery based on ketone level, and mitigate the risk of euglycemic diabetic ketoacidosis (euDKA).
Resumen de: WO2025188997A1
Disclosed herein are system, method, and computer program product embodiments for generating determining overnight hypoglycemia risk by estimating the likelihood of a hypoglycemic event occurring over a specified period of time, namely overnight. The disclosure describes utilizing two key aspects: factors that can disturb glucose levels are much less likely to occur overnight, and bedtime is a convenient and beneficial time for the patient to check for and mitigate their risk of hypoglycemia overnight.
Resumen de: WO2025189059A1
A method and system for establishing and executing a dynamic titration protocol for administration of an antidiabetic is disclosed. The method may include establishing an initial titration protocol and then applying an aggressiveness level to the initial titration protocol to obtain an initial use titration protocol. The initial use titration protocol may then be executed with a patient and glucose monitoring data may be received from the patient. The monitoring data may be used to perform a failsafe monitoring procedure and a revised aggressiveness level and titration protocol may be determined based on the results of the failsafe monitoring.
Resumen de: WO2025188774A1
An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg/dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg/dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.
Resumen de: WO2025188770A1
An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg/dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg/dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.
Resumen de: US2025281074A1
Embodiments of the invention provide amperometric analyte sensors having optimized elements such as dexamethasone rejection membranes as well as methods for making and using such sensors. The amperometric analyte sensor apparatus comprises: a base layer; a conductive layer disposed on the base layer and comprising a working electrode; an dexamethasone rejection membrane disposed over an electroactive surface of the working electrode, wherein the interference rejection membrane comprises a poly Hema composition and an analyte sensing layer. While embodiments of the innovation can be used in a variety of contexts, typical embodiments of the invention include glucose sensors used in the management of diabetes.
Resumen de: US2025281694A1
An infusion pump system providing therapy to a patient in a closed-loop or semi-closed loop mode can safely automatically revert to open-loop therapy. The system stores a default open- loop basal rate profile in memory. The system also continually tracks the insulin on board for the patient over a plurality of closed-loop therapy intervals. When an error or event occurs requiring reversion to open-loop therapy, the system automatically provides therapy according to the open- loop basal rate profile and the tracked insulin on board amount.
Resumen de: US2025281078A1
A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.
Resumen de: US2025281076A1
A system for continuous glucose measurement and spinal cord stimulation provides at least two implantable non-stimulation electrodes configured to continuously monitor at least one physiological parameter on a lead that also includes a plurality of implantable stimulation electrodes. The electrodes are electrically connected to an implantable pulse generator that communicates stimulation instructions and glucose measurement data.
Resumen de: US2025281126A1
Disclosed herein are system, method, and computer program product embodiments for generating determining overnight hypoglycemia risk by estimating the likelihood of a hypoglycemic event occurring over a specified period of time, namely overnight. The disclosure describes utilizing two key aspects: factors that can disturb glucose levels are much less likely to occur overnight, and bedtime is a convenient and beneficial time for the patient to check for and mitigate their risk of hypoglycemia overnight.
Resumen de: US2025281073A1
Described herein are systems and methods for non-invasive glucose detection using an optical sensing apparatus. The optical sensing apparatus comprises one or more single-photon avalanche diodes (SPADs) and one or more processors. The one or more SPADs may be configured to receive light pulses having one or more wavelengths that have interacted with biological tissues over a plurality of time cycles and convert the light pulses into a plurality of electrical signals. Each of the one or more SPADs may comprise an absorption region formed on a substrate, wherein the absorption region comprises germanium or germanium containing tin, and wherein the substrate comprises silicon. The one or more processors may be configured to identify, for each of the plurality of time cycles, particular time slots representing a time duration that each of the light pulses has interacted with glucose molecules and determine one or more characteristics of glucose molecules.
Resumen de: US2025281356A1
A glass container is characterized by a longitudinal axis (Ltube) that passes through a center of a glass bottom of the glass container. For any cut surface of the glass container that is obtainable by cutting the glass container in a plane that includes the longitudinal axis Ltube, a minimum thickness (smin) and a maximum thickness (smax) of the glass bottom determined at any position having a distance d1/4 or less to the longitudinal axis Ltube and a thickness (sd1/4) is the thickness of the glass bottom determined at a position having the distance d1/4 to the longitudinal axis Ltube, the distance to the longitudinal axis Ltube in each case being determined in a direction that is perpendicular to the longitudinal axis Ltube and thicknesses smin, smax and sd1/4 being determined in a direction that is parallel to longitudinal axis Ltube, with smax/smin being less than 1.8.
Resumen de: US2025281079A1
Methods and devices to detect analyte in body fluid are provided. Embodiments include generating signals indicative of a glucose level in the interstitial fluid, obtaining a plurality of data points from the signals generated by the glucose sensor, pairing the plurality of data points with reference data to form a plurality of pairs, estimating, based on the plurality of pairs, a first offset corresponding to a window of a time period, determining a time varying offset based on the first offset, and applying the time varying offset to the plurality of data points to estimate the glucose level.
Resumen de: US2025281080A1
Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. Each microneedle of the microneedle array may include a microneedle body, an electrode material on the microneedle body, a biorecognition layer on the electrode material, a diffusion-limiting layer on the biorecognition layer, an interferent blocking agent, and/or an attachment enhancer between the biorecognition layer and the diffusion-limiting layer, where the interferent blocking agent and the attachment enhancer are configured to improve sensor sensitivity variability.
Resumen de: US2025281075A1
A transdermal glucose monitoring system is provided. The system includes: a continuous glucose monitoring (CGM) device, configured to monitor glucose concentration in subcutaneous interstitial fluid of a patient; a patient user interface, configured to acquire information of the CGM device, receive glucose concentration data, and display a warm-up progress indicator of the CGM device; and a cloud server, configured to complete data sharing and authorize access to data. The provided patient user interface focuses on the warm-up time of the CGM device and provides a positive and intuitive display thereof, along with visual management of glucose monitoring data analysis, thereby enhancing the convenience of glucose monitoring. Furthermore, the system supports a second monitoring device, enabling family and friends to promptly understand the patient's glucose monitoring status and infer the causes of glucose fluctuations.
Resumen de: US2025281077A1
Techniques for glucose level management are disclosed. In some examples, the techniques may involve obtaining an estimated value of a first nutrient for a meal and an estimated value of a second nutrient for the meal. The techniques may further involve obtaining a patient-specific conversion factor that predicts a glucose level rise for a patient due to consumption of the first nutrient. The techniques may further involve converting the estimated value of the first nutrient into a corresponding value associated with the second nutrient using the patient-specific conversion factor to generate a conversion of the first nutrient. The techniques may further involve determining an equivalent value associated with the second nutrient for the meal based on the estimated value of the second nutrient and the conversion of the first nutrient.
Resumen de: US2025281111A1
Described herein are examples of systems and methods for determining the efficacy of a therapeutic intervention related to the treatment of diabetes. In an example, a continuous glucose monitor can be used to monitor the glucose levels of a subject. An insulin pump can administer insulin to the subject in response to the glucose levels obtained by the continuous glucose monitor. The efficacy of a treatment intervention can be determined by comparing an amount of insulin administered to the subject by the insulin pump over a timeframe associated with the treatment intervention to an amount of insulin administered to the subject by the insulin pump over a timeframe associated with a control or placebo period and/or a timeframe associated with a second treatment intervention.
Resumen de: US2025285734A1
Methods and systems are disclosed for prompting a patient to take a blood glucose management action. A diabetes management application on a mobile device can receive diabetes-related information from the mobile device. The diabetes management application can identify a blood glucose management action prompt based on a comparison of the received diabetes-related information to one or more predetermined prompt criteria. The diabetes management application can generate a blood glucose management action prompt based on the blood glucose management action prompt condition. The diabetes management application can present the blood glucose management action prompt to the patient on a user interface of the mobile device.
Resumen de: EP4614152A1
An object of the present invention is to provide an agent for inhibiting glucose uptake into red blood cells and a blood collection tube that suppresses glucose concentration decrease. According to the present invention, there is provided an agent for inhibiting glucose uptake into red blood cells, including inosine as an active ingredient. The inhibition agent of the present invention can be used for suppressing a decrease in glucose concentration of whole blood collected in a blood collection tube. According to the present invention, there is also provided a blood collection tube including inosine in an internal space. The blood collection tube of the present invention can be used to measure a glucose concentration in blood. The blood collection tube of the present invention can further include a glycolysis inhibitor.
Resumen de: EP4613192A1
A blood glucose measurement method, an electronic device (100), and a system are provided. The blood glucose measurement method includes: first determining a core temperature of a human body, determining a sensor temperature based on the core temperature, a skin temperature, and a physiological parameter, and performing temperature compensation on blood glucose measurement, to obtain a blood glucose concentration with higher accuracy.
Resumen de: AU2023372542A1
Embodiments can relate to a system for automatically detecting sensor compression in continuous glucose monitoring including at least one sensor and at least one processor in communication with the at least one sensor, the at least one processor executing at least two machine learning models, wherein the at least one processor is programmed or configured to cause the processor to receive, from the at least one sensor, measurement data including at least one time series of blood glucose (BG) measurements measured by the at least one sensor, determine that the at least one time series of BG measurements is a candidate series including a compression artifact using a first machine learning model, and generate, using a second machine learning model, a signal output indicating that the at least one time series of BG measurements was obtained while the at least one sensor was subject to compression.
Resumen de: AU2023372535A1
Embodiments can relate to systems and methods for automatically detecting sensor compression in continuous glucose monitoring in real time. A system may include at least one sensor and at least one processor in communication with the at least one sensor. The at least one processor is programmed or configured to cause the processor to retrieve first measurement data including at least one time series of blood glucose (BG) measurements, the at least one time series being measured by the at least one sensor while not subject to compression; receive, from the at least one sensor, second measurement data including at least one BG measurement; determine a clearance value between BG measurements based on the first measurement data and the second measurement data; and generate a signal output indicating that the at least one sensor is subject to compression based on the clearance value between BG measurements exceeding a predefined threshold.
Nº publicación: EP4613319A2 10/09/2025
Solicitante:
MEDTRONIC MINIMED INC [US]
Medtronic MiniMed, Inc
Resumen de: EP4613319A2
This invention pertains to systems and components useful for infusing medications such as insulin. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.
BOPI
Sede Electrónica
